A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT02774278 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

264

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG: Erlotinib

Sponsor

Hoffmann-La Roche